Daehwa Pharmaceutical signs Chinese technology transfer agreement of ‘Liporaxel Soln’ for USD 25 million

Published: 2017-09-11 16:26:00
Updated: 2017-09-11 14:41:34

Daehwa Pharmaceutical announced on the 6th that the company signed a technology transfer agreement of the world’s first approved oral paclitaxel anticancer drug(Korean product name: Liporaxel Soln) for USD 25 million and other royalties with Chinese RMX Biopharma.

The total technology licensing ...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.